Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

30 Aug 2016

• By Derrick Gingery

Capitol House

Related Content

Mylan's Generic EpiPen: A Good PR Move, But Risks Alienating Payers

29 Aug 2016

Cheap Drugs Create Quality Temptations, FDA Official Says

04 Dec 2015

Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

01 Mar 2016

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

21 Mar 2016

<em>Copaxone</em> Generics: FDA Approval Standards Defy Teva’s Argument On Complexity

27 Apr 2015

FDA's Combo Products Review Transformation Begins

24 Aug 2016

PDUFA First: Fees To Support Device Center Staff

24 Aug 2016

FDA To Update Quality Metrics Guidance

09 Aug 2016

Why Generic EpiPen Is Not The Answer – Until FDA Says It Is

29 Aug 2016

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Sanofi

Additional Topics

United States Legislation Review Pathway Drug Review Regulation Pricing Debate Combination Products BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.